Get the Stockscreener App
4.61
2.44%
0.11
Bioage Labs Inc stock is traded at $4.61, with a volume of 107.72K.
It is up +2.44% in the last 24 hours and down -3.15% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$4.50
Open:
$4.5
24h Volume:
107.72K
Relative Volume:
0.48
Market Cap:
$165.27M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.32%
1M Performance:
-3.15%
6M Performance:
+2.44%
1Y Performance:
+0.00%
1-Day Range:
$4.48
$4.65
1-Week Range:
$4.38
$4.6508
52-Week Range:
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.61 | 162.04M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
BioAge Labs to Present at Upcoming Investor Conferences - MarketScreener
Clinical-Stage Biotech BioAge Labs Announces Key Presentations at Citi and Morgan Stanley Healthcare Events - Stock Titan
BioAge Labs announces first participant dosed in Phase 1 trial of BGE-102 - MSN
BioAge commences dosing in trial of obesity treatment candidate BGE-102 - Yahoo Finance
Is BioAge Labs Inc. stock good for income investorsJuly 2025 Setups & Safe Investment Capital Preservation Plans - 선데이타임즈
Should I trade or invest in BioAge Labs Inc.Bear Alert & Technical Pattern Alert System - thegnnews.com
Can BioAge Labs Inc. Regain Lost Ground This Quarter2025 Buyback Activity & Weekly Top Stock Performers List - sundaytimes.kr
Market reaction to BioAge Labs Inc.’s recent newsBond Market & Verified High Yield Trade Plans - Newser
Should you hold or exit BioAge Labs Inc. nowWeekly Stock Report & Weekly Setup with High ROI Potential - Newser
BIOA FINAL DEADLINE: BioAge Labs Investors are Encouraged - GlobeNewswire
How BioAge Labs Inc. stock performs during market volatility2025 Growth vs Value & Daily Profit Maximizing Tips - beatles.ru
What institutional flow reveals about BioAge Labs Inc.July 2025 Levels & AI Based Buy and Sell Signals - Newser
BioAge Labs Reports Q2 2025 Financial Results and Progress - TipRanks
Earnings visualization tools for BioAge Labs Inc.July 2025 Analyst Calls & Real-Time Market Sentiment Reports - Newser
What’s the outlook for BioAge Labs Inc.’s sectorWeekly Gains Summary & Low Drawdown Investment Strategies - sundaytimes.kr
BioAge Labs: First Person Dosed in Phase 1 BGE-102 Trial - Lifespan Research Institute
BioAge Labs begins phase 1 trial of oral NLRP3 inhibitor for obesity - Investing.com Canada
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - MarketScreener
25% Weight Loss: BioAge's New Oral Drug Shows Breakthrough Results Combined with GLP-1s in Pre-Clinical Study - Stock Titan
BioAge Labs Inc. stock daily chart insightsWeekly Gains Summary & Weekly Watchlist for Consistent Profits - Newser
What data driven models say about BioAge Labs Inc.’s futureTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Is BioAge Labs Inc. a turnaround storyShort-Term Capital Growth Stocks - thegnnews.com
What is BioAge Labs Inc. s revenue forecast3x Potential Swing Trade Ideas - newsyoung.net
Q3 EPS Estimates for BioAge Labs Decreased by William Blair - Defense World
How to build a custom watchlist for BioAge Labs Inc.Real Time Growth Signal with Smart Setup - Newser
Real Time Data Flags Unusual Activity in BioAge Labs Inc.Consistent Gain Investment Strategies Emerge - beatles.ru
Smart tools for monitoring BioAge Labs Inc.’s price actionAI-Powered Stock Trend Movement Analysis - Newser
What makes BioAge Labs Inc. stock price move sharplyFree Growth Focused Entry Plan Suggestions - Newser
Cautious Outlook on BioAge Labs, Inc. Amid Uncertainties in Clinical Developments and Market Perception - TipRanks
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - The Motley Fool
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - Nasdaq
BioAge Labs, Inc. Advances Clinical Pipeline with BGE-102 Phase 1 Trial Set for 2H 2025 and Expands APJ Agonist Pipeline - Quiver Quantitative
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs Q2 2025: BGE-102 on track for Phase 1, expanded APJ pipeline, strengthened discovery platform. - AInvest
Full technical analysis of BioAge Labs Inc. stockFree Fundamental Growth Stock Analysis - Newser
What are the technical indicators suggesting about BioAge Labs Inc.Maximize your returns with expert insights - Jammu Links News
What catalysts could drive BioAge Labs Inc. stock higher in 2025Dynamic investment growth - Jammu Links News
What is BioAge Labs Inc. company’s growth strategyHigh-margin investment plays - Jammu Links News
How does BioAge Labs Inc. compare to its industry peersDiscover undervalued stocks before they soar - Jammu Links News
Is BioAge Labs Inc. a growth stock or a value stockSkyrocketing returns - Jammu Links News
Should I hold or sell BioAge Labs Inc. stock in 2025Rapid market gains - Jammu Links News
What are the latest earnings results for BioAge Labs Inc.Navigate the market with precision tools - Jammu Links News
BioAge Labs Requests to Dismiss Class Action Filed by Investors - TradingView
BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery - MSN
Published on: 2025-07-29 06:11:56 - beatles.ru
Price Channel Expanding on BioAge Labs Inc.’s ChartAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bioage Labs Inc Stock (BIOA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pande Vijay Satyanand | Director |
Oct 01 '24 |
Buy |
19.73 |
126,793 |
2,501,626 |
1,026,793 |
| Pande Vijay Satyanand | Director |
Oct 02 '24 |
Buy |
19.73 |
67,096 |
1,323,804 |
1,093,889 |
| Pande Vijay Satyanand | Director |
Oct 03 '24 |
Buy |
19.90 |
25,306 |
503,589 |
1,119,195 |
| Cormorant Asset Management, LP | Former 10% Owner |
Sep 27 '24 |
Buy |
18.00 |
450,000 |
8,100,000 |
1,629,529 |
| Pande Vijay Satyanand | Director |
Sep 27 '24 |
Buy |
18.00 |
900,000 |
16,200,000 |
900,000 |
| ENRIGHT PATRICK G | Director |
Sep 27 '24 |
Buy |
18.00 |
400,000 |
7,200,000 |
1,710,589 |
| HEALY JAMES | Director |
Sep 27 '24 |
Buy |
18.00 |
666,665 |
11,999,970 |
2,227,124 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):